Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention?
In this paper, the results of some recent studies on idiotype-specific T cells in human multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) are discussed. By using different in vitro measurements such as 3H-thymidine incorporation and ELI-SPOT assay, idiotype-specific T cells have been demonstrated in most of MM and MGUS patients. Based on the cytokine-secretion profiles, idiotype-specific T cells were found to comprise both Th1 and Th2 cells. A Th1 type immunity was found preferentially in indolent disease and a Th2-like response predominated in advanced MM, suggesting a specific T-cell regulation of the tumor B-cell clone. The mode of T-cell recognition of id determinants on M-components has been studied. We found that idiotype-specific T cells recognized processed id determinants presented by MHC class II (HLA-DR) molecules on APC. B cells were much more efficient APC than monocytes. With the aim to induce or to amplify an idiotype-specific T-cell response, we have immunized MM patients with the autologous M-component precipitated in aluminum. Three out of the five patients showed an induction of specific cellular and humoral immunity. Nevertheless, the role for such immunity in controlling the tumor clone remains to be established.
Yi
Q
Q
Immunological Research Laboratory, Karolinska Hospital, Stockholm, Sweden.
Osterborg
A
A
D000818:Animals; D000888:Antibodies, Anti-Idiotypic; D000918:Antibody Specificity; D002454:Cell Differentiation / Q000276:immunology; D002455:Cell Division / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D009101:Multiple Myeloma / Q000276:immunology* / Q000628:therapy; D010265:Paraproteinemias / Q000276:immunology* / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology*
D000888:Antibodies, Anti-Idiotypic